Apos® Selected as the First Technology Supported by NHS England’s MedTech Funding Mandate for 2024/25
AposHealth® a disruptive global company focused on revolutionising the treatment of musculoskeletal (MSK) conditions such as knee osteoarthritis (OA) is delighted to announce that its flagship solution Apos® has been chosen as the first new technology to receive support under the MedTech Funding Mandate (MTFM) for the coming financial year 2024/25. This important selection by […]